PrimeRFP SCOUT · Federal Contract Recompete Brief

75N90025F00003F-18 pylarify piflufolastat injection DRUGS FROM — Progenics Pharmaceuticals Inc

Progenics Pharmaceuticals Inc holds $95.0M across 149 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards under parent 36F79719D0170. The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: Small business. PoP ended Sep 29, 2026 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

National Institutes Of Health - Cc
Awarding office
Progenics Pharmaceuticals Inc
Recipient
Sep 29, 2026
PoP end
$2.1M
Obligated
$2.1M
Potential
325412
NAICS
6505
PSC
Small business
Set-aside
1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Small business
Contract number75N90025F00003
Also listed as36F79719D0170-75N90025F00003
AgencyNational Institutes Of Health - Cc
Awarding officeNational Institutes Of Health - Cc
Awarding agencyDepartment of Health and Human Services (HHS)
Funding agencyDepartment of Health and Human Services (HHS)
IncumbentProgenics Pharmaceuticals Inc
CAGE34KE9
UEIYLYKVRPCTCR3
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV36F79719D0170
Place of performanceNORTH BILLERICA MA
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
Related solicitationCS-120703-SB
PoP startOct 1, 2024
PoP end (current)Sep 29, 2026
Obligated$2.1M
Current value$2.1M
Potential value$2.1M

PIFLUFOLASTAT F-18 INJECTION DRUGS (PYLARIFY) FROM SOFIE CO. [POTS 25-000073] is a federal Small business award for National Institutes Of Health - Cc held by Progenics Pharmaceuticals Inc. Estimated value $2.1M ($2.1M obligated). Current period of performance ends Sep 29, 2026. Last award drew 1 bidder. Place of performance: NORTH BILLERICA MA. Related solicitation CS-120703-SB.

PIFLUFOLASTAT F-18 INJECTION DRUGS (PYLARIFY) FROM SOFIE CO. [POTS 25-000073]

Recompete timing

Public
● Past PoP end (1 days ago)

Current PoP ended Sep 29, 2026 (1 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Bonuses end Sept 30

Want the durability read on 75N90025F00003? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Progenics Pharmaceuticals Inc — $95.0M obligated across 149 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($95.0M) · all agencies
Department of Veterans Affairs (VA)$93.8M · 99%Department of Health and Human Services (HHS)$1.1M · 1%Department of Defense (DOD)$105K · 0%
Open full company profile →

Related awards

Same parent · incumbent
36C26122N0385
PYLARIFY (PIFLUFOLASTAT F18) NDC: 71258-0022-01
$4.5M
Sep 30, 2026
36C24826N0071
PYLARIFY (PIFLUFOLASTAT F 18) INJECTION
$1.2M
Sep 30, 2026
36C25026N0037
RADIOPHARMACEUTICAL PYLARIFY FSS BPA - BASE YEAR DELIVERY ORDER
$1.1M
Sep 30, 2026
75N90026F00006
PYLARIFY (PIFLUFOLASTAT F-18) FROM PROGENICS PHARMACEUTICALS INC.:1106332 [26-000012]
$886K
Sep 30, 2026
36C26126N0102
PYLARIFY (PIFLUFOLASTAT F-18)
$759K
Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 75N90025F00003?

75N90025F00003 (F-18 pylarify piflufolastat injection DRUGS FROM) is a National Institutes Of Health - Cc award with a potential value of $2.1M, currently held by Progenics Pharmaceuticals Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N90025F00003?

National Institutes Of Health - Cc awarded 75N90025F00003 to Progenics Pharmaceuticals Inc (potential $2.1M).

Who is the incumbent on 75N90025F00003?

Progenics Pharmaceuticals Inc is the incumbent with $95.0M across 149 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2026.

When does Progenics Pharmaceuticals Inc’s 75N90025F00003 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 29, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 75N90025F00003? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75N90025F00003